Eosinophilic gastroenteritis following COVID-19 mRNA vaccination
Introduction: Large-scale clinical studies for COVID-19 vaccines have shown the infection-preventing effect and short-term adverse effects. Some rare illnesses such as eosinophilia can develop following COVID-19 vaccinations. Case description: We report a case of 65-year-old man with unexplained abd...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMC MEDIA SRL
2024-02-01
|
| Series: | European Journal of Case Reports in Internal Medicine |
| Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/4316 |
| Summary: | Introduction: Large-scale clinical studies for COVID-19 vaccines have shown the infection-preventing effect and short-term adverse effects. Some rare illnesses such as eosinophilia can develop following COVID-19 vaccinations.
Case description: We report a case of 65-year-old man with unexplained abdominal pain that developed 2 weeks after COVID-19 mRNA vaccination. The patient had received a second dose of COVID-19 mRNA vaccine and revealed eosinophilia at the first visit to our hospital. Eosinophil infiltration was observed in the lamina propria of the duodenum by a step biopsy. Montelukast 10 mg was administered as the initial treatment of eosinophilic gastroenteritis (EGE), and the abdominal pain was improved.
Discussion: The strong influence of COVID-19 vaccination on the development of EGE remains unproven. Reports of eosinophilia following COVID-19 vaccination have discussed that COVID-19 mRNA vaccination triggered an eosinophilic response.
Conclusion: This case presented EGE that developed following COVID-19 mRNA vaccination, which would be a rare adverse event. |
|---|---|
| ISSN: | 2284-2594 |